Biogen is presenting long-term Phase 3 data on pegcetacoplan and investigational felzartamab across seven kidney disease programmes at ASN Kidney Week.

Coultreon Biopharma presented final Phase 1 data on its oral SIK3 inhibitor at UEGW 2026, with Phase 2 psoriasis recruitment set for Q4 2026.

Phase 3 GALAXI data and new FUZION fistula results presented at UEG Week 2026 extend the evidence base for guselkumab in Crohn's disease.

GSK's Jemperli becomes the first immunotherapy cleared for locally advanced MSI-H/dMMR rectal cancer, backed by AZUR-1 trial data showing 68% complete

Japan's MHLW has cleared the CirCLIQ injector for Sanofi's isatuximab SC formulation, making it the first anticancer therapy delivered via an on-body

The IBA-Framatome joint venture will use Telix's RLS radiopharmacy network to commission its first US Astatine-211 production unit in Pennsylvania.

Telix Pharmaceuticals and the IBA-Framatome joint venture Ekalia will install an alpha-beam cyclotron near Philadelphia to produce scarce astatine-211 for targeted alpha

Four-year first-in-human data show sustained intraocular pressure reduction and 86% of glaucoma patients remaining drop-free after cataract surgery.

Disc Medicine said its oral GlyT1 inhibitor bitopertin met co-primary and all secondary endpoints in 183 patients with erythropoietic protoporphyria.

Quanta Therapeutics secured FDA Fast Track designation for QTX3034 in KRAS G12D-mutant colorectal cancer ahead of clinical data presented at ESMO 2026.

Phase 1 healthy-volunteer data show potent, durable TSHR engagement from a single dose, as Ethyreal opens patient cohorts in TED and Graves' disease.

An IDE supplement expands the REGAIN recurrent glioblastoma trial from 10 to 20 patients, adding survival endpoints and a new interim analysis.